My Cart

CXCR4

CXCR4 Overview

English NameC-X-C motif chemokine receptor 4Approved Drugs3
Drugs in Clinical Trials24Target SynonymNPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine (C-X-C Motif) Receptor 4,CD184 Antigen,C-X-C Motif Chemokine Receptor 4,Lipopolysaccharide-Associated Protein 3
Highest Development StageApproved
English NameC-X-C motif chemokine receptor 4
Target SynonymNPYRL,CD184,CXCR4,CXC-R4,SDF-1 receptor,LAP-3,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C Motif), Receptor 4 (Fusin),Seven Transmembrane Helix Receptor,C-X-C Chemokine Receptor Type 4,Neuropeptide Y Receptor Y3,Neuropeptide Y3 Receptor,Chemokine Receptor,D2S201E,HSY3RR,NPYY3R,CXCR-4,NPY3R,WHIMS,LAP3,NPYR,WHIM,Receptors, CXCR4,LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine (C-X-C Motif) Receptor 4,CD184 Antigen,C-X-C Motif Chemokine Receptor 4,Lipopolysaccharide-Associated Protein 3
Approved Drugs3
Drugs in Clinical Trials24
Highest Development StageApproved

CXCR4 Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (5)

  • Species

    Human (3)

  • Tag

    Fc Tag (1)- (3)His Tag & Flag Tag (1)

  • Conjugate

    Unconjugated (3)

CXCR4 Background

C-X-C chemokine receptor type 4 is also known as fusin or CD184 (cluster of differentiation 184), CXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R or WHIM. CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

CXCR4 Synonyms

CXCR4,CD184,Fusin,D2S201E,FB22,HM89,HSY3RR,LAP3,LCR1,LESTR,NPY3R,NPYR,NPYRL,NPYY3R,WHIM

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
CXCR4 mAb - 01LeadMonoclonalHumanized MouseHematological Malignancy,AutoImmunityBlood tumor,Solid tumor
DLL3 mAb - 01LeadMonoclonalFull HumanSolid TumorSmall cell lung cancer

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
[68Ga]Pentixafor[68Ga]Ga-PentixaFor; CXCR4-PET; 68Ga-PTF; [68Ga]Ga-PentixaFor PET/CT; [68Ga]Ga-PTFPhase 3 ClinicalThe University Of Iowa, Pentixapharm AGLymphoma, B-Cell, Marginal Zone; Cushing Syndrome; Sarcoidosis; Rejection of organ transplantation; Neuroendocrine Tumors; Multiple Myeloma; Histiocytosis, Sinus; Erdheim-Chester Disease; Histiocytic Sarcoma; Myocarditis; Lymphoma, Non-Hodgkin; Hyperaldosteronism; Central Nervous System Lymphoma
Details
90Y-PentixatherPhase 2 ClinicalUniversity Of Wurzburg, Technical University Of MunichMultiple Myeloma; Central Nervous System Lymphoma
Details
177Lu-PentixatherPhase 2 ClinicalTechnical University Of Munich, Nantes University Hospital, University Of WurzburgLeukemia; Multiple Myeloma
Details
Burixafor HydrobromideTG-0054; GP 01; GPC-100; TG-3000Phase 2 ClinicalTaiGen Biotechnology Co LtdHematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Multiple Myeloma; Prostatic Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute
Details
MSX-122Q-122; WZ-40; MSX-122Phase 2 ClinicalAltiris TherapeuticsSolid tumours; Hot Flashes
Details
PTX-9908PTX-9908Phase 2 ClinicalPertinax TherapeuticsCarcinoma, Hepatocellular
Details
Ga-68-CXCR4Ga-68-CXCR4Phase 2 ClinicalKoo Foundation Sun Yat-Sen Cancer CenterLymphoma, B-Cell
Details
Plerixafor/Tacrolimus HydrateAMD3100+FK506; MRG-001(MedRegen)Phase 2 ClinicalMedRegen LLCMotor Neuron Disease; Cytokine Release Syndrome; Hepatitis, Alcoholic; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries; Respiratory Insufficiency; Amyotrophic Lateral Sclerosis
Details
NRP-2945NRP-2945; NNZ-4945Phase 2 ClinicalNeuren Pharmaceuticals Ltd, Calzada LtdAngelman Syndrome; Rett Syndrome; Lennox Gastaut Syndrome; Epilepsy, Absence; Epilepsy, Temporal Lobe; Amyotrophic Lateral Sclerosis
Details
4-P-0214P021; 4-P-021Phase 2 Clinical4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De LilleCoronavirus Disease 2019 (COVID-19)
Details
CGT-1881CGT1881; CGT-1881Phase 2 ClinicalCgenetech(Suzhou China) Co LtdHematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin
Details
AGT 103-TAGT 103-TPhase 1 ClinicalAmerican Gene Technologies International IncHIV Infections
Details
BalixafortidePOL-6326Phase 1 ClinicalPolyphor LtdLeukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell
Details
JVS-100JVS-100; SRX-100; ACRX-100; GP-51801; GP51801Phase 1 ClinicalCleveland ClinicHeart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease
Details
CXCR4 modulator(Ligand/Upsher Smith)Phase 1 ClinicalLigand Pharmaceuticals IncNeoplasms
Details
GP-8012GP-8012; GP8012Phase 1 ClinicalNanjing Gritpharma Co LtdIschemia; Peripheral Arterial Disease
Details
68Ga-JH1268Ga-JH12Phase 1 ClinicalFirst Affiliated Hospital Of Fujian Medical UniversityNeoplasms
Details
203-Lead PentixatherPhase 1 ClinicalNational Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer CenterSmall Cell Lung Carcinoma; Lung Neoplasms
Details
212-Lead PentixatherPhase 1 ClinicalNational Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer CenterSmall Cell Lung Carcinoma; Lung Neoplasms
Details
68Ga-Pentixather68Ga-PentixatherPhase 1 ClinicalPeking Union Medical College HospitalMultiple Myeloma
Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityMultiple Myeloma
Details
AD-214AD-214Phase 1 ClinicalAdalta LtdLung Diseases, Interstitial
Details
X-4136X-4136ClinicalX4 Pharmaceuticals IncLymphoma, B-Cell; Melanoma; Uterine Cervical Neoplasms
Details
[18F]AlF-NOTA-pentixatherSichuan Provincial People'S Hospital
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
PlerixaforSDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100ApprovedGenzyme CorpMozobil, Mobozil, 释倍灵United StatesLymphoma, Non-Hodgkin; Multiple MyelomaGenzyme Corp2008-12-15Agranulocytosis; Pulmonary Fibrosis; Rejection of organ transplantation; Respiratory Distress Syndrome, Adult; Leukopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Osteosarcoma; Colorectal Neoplasms; Lymphopenia; Multiple Myeloma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Lymphoma; Granulomatous Disease, Chronic; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia, Sickle Cell; WHIM syndrome; Hematopoietic stem cell transplantation (HSCT); Cystic Fibrosis; Infections; Leukemia, Myelogenous, Chronic; Wiskott-Aldrich Syndrome; Ovarian Neoplasms; Hematologic Neoplasms; Neutropenia; Bone metastases; Warts; Primary Graft Dysfunction; Coronavirus Disease 2019 (COVID-19); Fanconi Anemia; Hodgkin Disease; Pancreatic Neoplasms; Myelodysplastic Syndromes
Details
MavorixaforAMD-11070; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081; X4P-001-IOApprovedGenzyme CorpXOLREMDI, XolremdiUnited StatesWHIM syndromeX4 Pharmaceuticals Inc2024-04-26HIV Infections; WHIM syndrome; Neutropenia; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Hepatic Insufficiency; Waldenstrom Macroglobulinemia; Melanoma
Details
Motixafortide4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168; 4F-benzoyl-TN-14003ApprovedBiokine, Kyoto UniversityAPHEXDAUnited StatesHematopoietic stem cell transplantation (HSCT)Biolinerx Ltd2023-09-08Leukemia, Myelogenous, Chronic; Hematopoietic stem cell transplantation (HSCT); Esophageal Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hodgkin Disease; Pancreatic Neoplasms; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Anemia, Sickle Cell; Adenocarcinoma
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland